← Back to Search

Behavioural Intervention

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

N/A

Waitlist Available

Led By Sagar D Sardesai, MSPH, PhD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 10 years

Awards & highlights

No Placebo-Only Group

Summary

This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve prevention strategies, and provide timely intervention for early therapeutic management as needed.

Eligible Conditions

Fibrocystic breast changes
Breast ADH
Breast Cancer
Atypical Lobular Hyperplasia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Time to breast cancer events during study follow up

Secondary study objectives

Bone marrow index

Mammographic breast density

Waist circumference

+1 more

Other study objectives

Proportion of patients initiating chemoprevention during study follow up

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Observational (physical exam, questionnaire)Experimental Treatment3 Interventions

Patients complete physical measurements every 6 months and complete questionnaires annually for 5 years. Patients are followed up annually in years 5-10.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Follow-Up

2019

N/A

~50

Physical Examination

2019

Completed Phase 1

~1200